Teva's Q2 revenues flat on European rise, U.S. fall

The good news from Teva Pharmaceutical Industries: Last year's acquisition of Ratiopharm hiked European sales for the second quarter. The not-so-good: A lack of new product introductions and erosion in sales of key products offset that rise, leaving sales flat. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.